prof. dr. P. (Peter) van der Meer

Education/Academic background

2011 Registration as Cardiologist; 2005-2011 Residency Cardiology-Deventer Ziekenhuis - UMCG; 2007-2008 Post-doctoral fellow, Harvard University, Boston, USA; 2002-2005 PhD in Medicine (cum laude), University of Groningen; 1995-2002 Medicine (cum laude), University of Groningen.

Current job title: Full-professor in Cardiology / Cardiologist. Chair Experimental Cardiology, Department of Cardiology, University Medical Center Groningen, the Netherlands. Medical License no: 19057834301

Profile: Prof. Van der Meer is a cardiologist working on clinical and translational research topics to bridge the gap between bench and bedside. His work focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies in heart failure.

 Scientific track record.

1. Selected publications:

Van der Pol A, …, Van der Meer P. Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH Science Transl Med 2017.  Hoes M, …., Van der Meer P. Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation. 2020. Ponikowski,…, Van der Meer P, … Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020. Vermeer M, …., Van der Meer P. Gain-of-function mutation in ubiquitin-ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. J Clin Invest 2021 Grote Beverborg N, …, Van der Meer P. Phospholamban Antisense Oligonucleotides Improve Cardiac Function in Murine Cardiomyopathy. Nat Comm. 2021  

Number of publications: ~350, H-index: 78

Scientific grants (ongoing): 2014 Human Frontier Science Programme: Understanding emergence and loss of synchrony in excitable tissue $375,000; 2016 ERC StG: STOP-HF € 1,500,000. 2018 Dutch Heart Foundation/PPS: High throughput Screening to identify novel molecules enhancing the activity of the CArdio-Protective Enzyme 5-oxoprolinase (OPLAH) for the treatment of Heart Failure. – eSCAPE-HF € 250,000. 2018 Dutch Heart Foundation: Phase 3 morbidity/mortality trial: low dose digoxin to improve outcome in HF [co-PI]. € 3,000,000. 2021: NWO-ENW: M grant € 355,000 to study effects of selenium deficiency on cardiac function.2022 ERC CoG: DISSECT-HF € 2,000,000. 2023: GEREMY project. - € 1,050,000

Professional track record:

2020-present: Member NWO VIDI committee; 2016-present Member of the executive committee of a large multinational phase III placebo controlled  morbidity & mortality trial with intravenous iron (N=1,100 patients); 2019-present: Co-PI phase 3 M&M trial with low dose digoxin in chronic heart failure. 2015-2020 Member task force: Heart Failure Guidelines 2016, ESC

Valorisation track record:-Generation of cardiac tissue with Cardiac Progenitor Cells.HU 3281/MGH 3703(030258-062520-P). -Circulating microRNAs in patients with acute heart failure.15155927.5-1404